Glaukos Announces Participation in the J.P. Morgan Healthcare Conference

Rhea-AI Summary

Glaukos Corporation (NYSE: GKOS) will participate in the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 5:15 p.m. PT in San Francisco, CA. This event highlights Glaukos' focus on innovation in ophthalmic medical technology and pharmaceuticals, specifically targeting glaucoma and other ocular disorders. A live and archived webcast will be available on their investor relations website, providing insights into their ongoing development of novel therapies and medical devices aimed at advancing treatment standards.

Positive

• Participation in a major healthcare conference increases visibility and investor engagement.
• Focus on innovative therapies for glaucoma and ocular disorders demonstrates commitment to advancing medical technology.

Negative

• None.

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the 41^st Annual J.P Morgan Healthcare Conference on Tuesday, January 10, 2023, at 5:15 p.m. PT in San Francisco, CA.

A live and archived webcast for this event will be available in the Investors section of the Glaukos website at http://investors.glaukos.com.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012, and continues to develop a portfolio of technologically distinct and leverageable platforms to support ongoing pharmaceutical and medical device innovations. Products or product candidates for each of these platforms are designed to advance the standard of care through better treatment options across the areas of glaucoma, corneal disorders and retinal diseases.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221228005284/en/

Chris Lewis

Vice President, Investor Relations & Corporate Affairs

(949) 481-0510

clewis@glaukos.com

Source: Glaukos Corporation

FAQ

What event is Glaukos Corporation participating in on January 10, 2023?

Glaukos Corporation is participating in the 41st Annual J.P. Morgan Healthcare Conference.

What time is Glaukos presenting at the J.P. Morgan Healthcare Conference?

Glaukos will present at 5:15 p.m. PT.

Where is the J.P. Morgan Healthcare Conference taking place?

The conference will be held in San Francisco, CA.

How can I access the Glaukos presentation?

The presentation can be accessed via a live and archived webcast on the Glaukos investor relations website.

What is the focus of Glaukos Corporation?

Glaukos Corporation focuses on developing therapies for glaucoma, corneal disorders, and retinal diseases.